Abstract: The invention relates to a combination of a protein phosphatase type 2C as an enzyme and a phospho-BAD as substrate. The protein BAD is dephosphorylated in position Ser155. Furthermore, the combination is used in an in vitro screening for ligands which modulate protein phosphatase type 2C, comprising the steps: incubating the protein phosphatase type 2C in combination with the substrate phospho-BAD and the ligand of the assay and detecting the decrease in phospho-BAD and/or the increase in phosphate and/or BAD. Therefore, new drugs for the treatment apoptosis may be found.

Abstract: The invention relates to a device for magnetic separation of pharmaceutical preparations, their starting or intermediate products that contain a separation space, in which a magnetic gradient field prevails and which has an inlet and an outlet, whereby the device is embodied in the form of an attachment filter for injection instruments or infusion instruments.

Abstract: Matrix-transdermal system that contains (21S)-21-hydroxy-21-methyl-14,17-ethano-19-norpregna-4,9,15-triene-3,20-dione that comprises a polyacrylate adhesive.

Abstract: The invention relates to a protein that binds specifically to the EDb-fibronectin domains, process for screening compounds that bind to a receptor of the EDb-fibronectin domains or to EDb-fibronectin domains themselves, as well as the uses of protein.

Abstract: Benzocycloheptenes of general formula I in which R1, R2 and Y have the meanings indicated herein, have antiestrogenic activity on and are suitable for the production of pharmaceutical agents, especially for prophylaxis and therapy of osteoporosis.

Abstract: The present invention relates to steroid compounds of general formula X, which may advantageously be employed to stimulate meiosis in human oocytes, the steroid being specifically characterized by amino nitrogen bonded to C17 of the steroid skeleton via a spacer A.

Abstract: Cascade polymer complexes with at least 16 ions of an element of atomic numbers 20 to 29, 39, 42, 44 or 57-83, useful NMR or x-ray lymphography imaging.

Abstract: The subject of the invention is a multi-stage process for the production of narrowly-distributed gas-filled microcapsules. In one process step, polymerization of the shell-shaping substance(s) takes place, and in a process step that is separated from it in space and/or time, the formation of the microcapsules by a build-up process takes place. The build-up process is carried out by low-energy defined gas input of the gas that is to be encapsulated with the aid of a porous membrane that has small defined pore openings.

Abstract: A new process for the preparation of diethylenetriaminepentaacetic-monoamides in which amines can be reacted with sensitive groups, a higher mono/diamide selectivity is achieved, a higher yield of monoamide is achieved and has a simple reaction scheme and working-up.

Abstract: This invention is directed to the use of radiopharmaceuticals in diagnosing Alzheimer's disease. In particular the radiopharmaceuticals of the invention are able to pass through the blood-brain barrier and bind to the CCR1 receptor present in brain tissue of patients having Alzheimer's disease.

Abstract: Aryl-substituted indirubin derivatives, their production and their intermediate products for production, as well as their use as medications for treating cancer, such as solid tumors and leukemia; auto-immune diseases, such as psoriasis, alopecia and multiple sclerosis, chemotherapy agent-induced alopecia and mucositis; cardiovascular diseases, such as stenoses, arterioscleroses and restenoses; infectious diseases, such as, e.g., those caused by unicellular parasites, such as trypanosoma, toxoplasma or plasmodium, or those caused by fungi; nephrological diseases, such as, e.g., glomerulonephritis; chronic neurodegenerative diseases, such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases, such as ischemias of the brain and neurotraumas; viral infections, such as, e.g., cytomegalic infections, herpes, hepatitis B and C, and HIV diseases, are described.

Abstract: The invention relates to crystalline lithium complexes of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane, their production and the recovery of the salt-free gadolinium complex of N-(1-hydroxymethyl-2,3-dihydroxypropyl)-1,4,7-triscarboxymethyl-1,4,7,10 tetraazacyclododecane from the latter without the use of ion exchangers.

Abstract: Sulfanyl-indirubin derivatives, their production and their intermediate products for production, as well as their use as medications for treating cancer, such as solid tumors and leukemia; auto-immune diseases, such as psoriasis, alopecia and multiple sclerosis, chemotherapy agent-induced alopecia and mucositis; cardiovascular diseases, such as stenoses, arterioscleroses and restenoses; infectious diseases, such as, e.g., those caused by unicellular parasites, such as trypanosoma, toxoplasma or plasmodium, or those caused by fungi; nephrological diseases, such as, e.g., glomerulonephritis; chronic neurodegenerative diseases, such as Huntington's disease, amyotrophic lateral sclerosis, Parkinson's disease, AIDS dementia and Alzheimer's disease; acute neurodegenerative diseases, such as ischemias of the brain and neurotraumas; viral infections, such as, e.g., cytomegalic infections, herpes, hepatitis, B and C, and HIV diseases, are described.

Abstract: Perfluoroalkyl-containing complexes with polar radicals of general formula I

Abstract: Perfluoroalkyl-containing complexes with sugar radicals of general formula I 1

Abstract: Cascade polymers, containing complex-forming ligands, optionally at least five ions of an element of atomic numbers 21-29, 39, 42, 44 or 57-83, as well as, if desired, cations of inorganic and/or organic bases, amino acids or amino acid amides, are valuable complexing compounds and complexes for diagnostics and therapy.

Abstract: Competitive progesterone antagonists, including two novel steroids, viz., 11&bgr;,19-[4-(cyanophenyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one and 11&bgr;,19-[4-(3-pyridinyl)-o-phenylene]-17&bgr;-hydroxy-17&agr;-(3-hydroxyprop-1(Z)-enyl)-4-androsten-3-one, inhibit formation of endometrial glands at below their ovulation inhibiting dose and the abortive dose, and thus achieve oral contraception in females without adversely affecting the menstrual cycle and without risk of aborting a previous implanted fertilized egg or a fetus.

Abstract: The invention relates to compounds of general formula I

Abstract: A soluble, heterodimeric interleukin 18 (IL-18) receptor molecule is described which comprises two subunits, one of which comprises an extracelluar domain, or a fragment thereof, of IL-18R, and the other of which comprises an extracelluar domain, or a fragment thereof, of AcPL. Preferably, the soluble, heterodimeric receptor binds to IL-18 with higher affinity than does either IL-18R or AcPL alone.